| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/03/2005 | CA2529238A1 Triazolotriazine compounds and uses thereof |
| 02/03/2005 | CA2528586A1 Cyclohexanecarboxylic acid compound |
| 02/03/2005 | CA2528043A1 Marks as modifiers of the pten pathway and methods of use |
| 02/03/2005 | CA2526240A1 7a5/prognostin and use thereof for the diagnostic and therapy of tumors |
| 02/03/2005 | CA2525829A1 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/02/2005 | EP1502962A2 Methods for assessing and treating cancer |
| 02/02/2005 | EP1502915A1 Compounds with a sulfamate group |
| 02/02/2005 | EP1502604A1 Use of nitric oxide mimetics in cancer treatment |
| 02/02/2005 | EP1502603A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM |
| 02/02/2005 | EP1502599A1 Active antiangiogenic therapy |
| 02/02/2005 | EP1502590A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes |
| 02/02/2005 | EP1501936A2 Cytokine protein family |
| 02/02/2005 | EP1501930A2 Oligomeric compounds for the modulation hif-1alpha expression |
| 02/02/2005 | EP1501923A2 Pak5-related compositions and methods |
| 02/02/2005 | EP1501921A1 Improved viral purification methods |
| 02/02/2005 | EP1501919A1 Soya cell strains with high isoflavone content |
| 02/02/2005 | EP1501866A2 Apo-2 ligand variants and uses thereof |
| 02/02/2005 | EP1501860A2 Modulation of heat-shock-protein-based immunotherapies |
| 02/02/2005 | EP1501857A2 Novel pancortin-pablo protein interactions and methods of use thereof |
| 02/02/2005 | EP1501856A2 Anti-her2 antibody variants |
| 02/02/2005 | EP1501855A2 Novel compositions and methods in cancer |
| 02/02/2005 | EP1501837A1 Cascade esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501836A1 Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds |
| 02/02/2005 | EP1501835A2 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
| 02/02/2005 | EP1501834A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501833A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501831A1 Inhibitors of checkpoint kinases (wee1 and chk1) |
| 02/02/2005 | EP1501827A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acid and their use as protease inhibitors |
| 02/02/2005 | EP1501819A1 Estrogen receptor modulators |
| 02/02/2005 | EP1501814A1 Semicarbazide derivatives for combating thromboembolic diseases |
| 02/02/2005 | EP1501812A1 Pna monomer and precursor |
| 02/02/2005 | EP1501803A2 Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity |
| 02/02/2005 | EP1501800A1 Bombesin antagonists |
| 02/02/2005 | EP1501799A1 Compounds useful in preparing camptothecin derivatives |
| 02/02/2005 | EP1501797A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501796A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo[b]thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors |
| 02/02/2005 | EP1501794A1 Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| 02/02/2005 | EP1501790A2 Novel sodium channel blockers |
| 02/02/2005 | EP1501787A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists |
| 02/02/2005 | EP1501774A1 Polyunsaturated linear aldehydes and their derivatives with anti-radical and anti-tumoral activity |
| 02/02/2005 | EP1501566A1 Medical products comprising a haemocompatible coating, production and use thereof |
| 02/02/2005 | EP1501565A1 Compounds and method for coating surfaces in a haemocompatible manner |
| 02/02/2005 | EP1501550A1 Non-viral gene delivery system |
| 02/02/2005 | EP1501547A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm |
| 02/02/2005 | EP1501545A2 Use of tnfalpha antibodies and another drug |
| 02/02/2005 | EP1501544A2 Alcam and alcam modulators |
| 02/02/2005 | EP1501537A1 Mannose binding lectin and uses thereof |
| 02/02/2005 | EP1501525A1 Method for producing preparations rich in tocotrienol |
| 02/02/2005 | EP1501524A2 Internal image antibodies for optical imaging and therapy |
| 02/02/2005 | EP1501522A2 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents |
| 02/02/2005 | EP1501515A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 02/02/2005 | EP1501514A2 Protein kinase modulators and methods of use |
| 02/02/2005 | EP1501512A2 4-azasteroid derivatives as androgen receptor modulators |
| 02/02/2005 | EP1501508A1 Inhibitors of histone deacetylase |
| 02/02/2005 | EP1501504A1 1-substituted imidazole derivatives as nos inhibitors |
| 02/02/2005 | EP1501503A1 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatment of central nervous system disturbances |
| 02/02/2005 | EP1501497A2 Catechin multimers as therapeutic drug delivery agents |
| 02/02/2005 | EP1501495A1 Use of pleuromutilins for the treatment of disorders caused by helicobacter pylori |
| 02/02/2005 | EP1501491A2 Methods and compositions for treatment of cancer pain |
| 02/02/2005 | EP1501489A1 Combination therapy for the treatment of cancer |
| 02/02/2005 | EP1501485A1 High drug load tablet |
| 02/02/2005 | EP1501482A1 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
| 02/02/2005 | EP1501359A2 Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
| 02/02/2005 | EP1440161A4 7118, a human arginine n-methyltransferase family member and uses therefor |
| 02/02/2005 | EP1436382A4 9136, a human aldehyde dehydrogenase family member and uses therefor |
| 02/02/2005 | EP1404334A4 Targeted delivery of bioaffecting compounds for the treatment of cancer |
| 02/02/2005 | EP1379257A4 Prodrugs of anticancer agents employing substituted aromatic acids |
| 02/02/2005 | EP1362050B1 Pyrimidine derivatives for inhibition of cell-proliferation |
| 02/02/2005 | EP1351980A4 Peptides for activation and inhibition of delta pkc |
| 02/02/2005 | EP1292591B1 Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| 02/02/2005 | EP1181283B1 Diaminothiazoles and their use for inhibiting protein kinases |
| 02/02/2005 | EP1165534B1 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 02/02/2005 | EP1161235B1 Combinations for the treatment of diseases involving angiogenesis |
| 02/02/2005 | EP1124779B1 Vitamin d analogues |
| 02/02/2005 | EP1064014B1 Medicament for preventing or treating papilloma virus-specific tumors |
| 02/02/2005 | EP0981610B1 Compositions for treatment of disorders involving programmed cell death |
| 02/02/2005 | EP0966534B1 Compositions and methods for elimination of unwanted cells |
| 02/02/2005 | EP0851769B1 Gene therapy using ovine adenoviral vectors |
| 02/02/2005 | CN1575338A Bv8 nucleic acids and polypeptides with mitogenic activity |
| 02/02/2005 | CN1575337A Mammalian receptor proteins; related reagents and methods |
| 02/02/2005 | CN1575303A Human CDR-grafted antibodies and antibody fragments thereof |
| 02/02/2005 | CN1575300A Telomerase inhibitory peptides and uses thereof |
| 02/02/2005 | CN1575299A Homing peptides |
| 02/02/2005 | CN1575297A Stabilization of amrubicin hydrochloride |
| 02/02/2005 | CN1575292A Pharmaceutically acceptable salts of 20(s)-camptothecins |
| 02/02/2005 | CN1575289A 6-hydroxy isoflavon compounds, their derivatives and medicaments involving the same |
| 02/02/2005 | CN1575286A Thiophene-amd thiazolesulfonamides as antineoplastic agents |
| 02/02/2005 | CN1575283A Piperazine derivatives with CCRI receptor antagonist activity |
| 02/02/2005 | CN1575182A Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/02/2005 | CN1575177A Cxcr3 antagonists |
| 02/02/2005 | CN1575176A Process for making substituted pyrazoles |
| 02/02/2005 | CN1575174A Pharmaceutically active isoindoline derivatives |
| 02/02/2005 | CN1575168A Combinations comprising a selective cyclooxygenase-2 inhibitor |
| 02/02/2005 | CN1572801A Double functional fusion protein possessing antineoplastic functions, method for making same and use thereof |
| 02/02/2005 | CN1572792A Pyrazolo [4, 3-d] pyrimidine derivatives |
| 02/02/2005 | CN1572327A Preparation of vaccine against tumor using differential library and its use |
| 02/02/2005 | CN1572324A Adjuvant composition |
| 02/02/2005 | CN1572320A Method for erythropoietin administration using pharmacokinetic and pharmacodynamic modeling |
| 02/02/2005 | CN1187442C Method for transferring antigens to dendritic cells |
| 02/02/2005 | CN1187373C Human resourced monoclone antibody of anti-blood-vessel endothelium growth factor as well as its preparing method and medicine composition |